Treatment with desmopressin acetate to reduce blood loss after cardiac surgery

E. W. Salzman, M. J. Weinstein, R. M. Weintraub, J. A. Ware, R. L. Thurer, L. Robertson, A. Donovan, T. Gaffney, V. Bertele, J. Troll

Research output: Contribution to journalArticle

340 Citations (Scopus)

Abstract

Bleeding after cardiopulmonary bypass remains a cause for concern, requiring reexploration of the chest in approximately 3 percent of patients who have had operations on the heart. We examined the possibility that this problem might be alleviated by desmopressin acetate (DDAVP), which increases the plasma level of von Willebrand factor and improves hemostasis in mild hemophilia and other conditions associated with defective platelet function. In a double-blind, prospective, randomized trial, we studied the effect of intraoperative desmopressin acetate in 70 patients undergoing various cardiac operations requiring cardiopulmonary bypass. Patients undergoing uncomplicated primary coronary-artery bypass grafting were not included. The drug significantly reduced mean operative and early postoperative blood loss (1317 ± 486 ml in the treated group vs. 2210 ± 1415 ml in the placebo group); of the 14 patients whose 24-hour blood loss exceeded 2000 ml, 11 had received the placebo. Plasma levels of von Willebrand factor were higher after desmopressin acetate than after placebo. Patients with the most bleeding had relatively low levels of von Willebrand factor before operation, suggesting a role for this factor in the hemorrhagic tendency induced by extracorporeal circulation. There were no untoward side effects of desmopressin acetate. We conclude that the administration of desmopressin acetate can be recommended to reduce blood loss in patients undergoing complex cardiac operations. The beneficial effect of the drug on hemostasis after cardiopulmonary bypass may be related to its effect on von Willebrand factor.

Original languageEnglish
Pages (from-to)1402-1406
Number of pages5
JournalNew England Journal of Medicine
Volume314
Issue number22
Publication statusPublished - 1986

Fingerprint

Deamino Arginine Vasopressin
Thoracic Surgery
von Willebrand Factor
Cardiopulmonary Bypass
Placebos
Hemostasis
Therapeutics
Hemorrhage
Postoperative Hemorrhage
Extracorporeal Circulation
Hemophilia A
Coronary Artery Bypass
Pharmaceutical Preparations
Thorax
Blood Platelets

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Salzman, E. W., Weinstein, M. J., Weintraub, R. M., Ware, J. A., Thurer, R. L., Robertson, L., ... Troll, J. (1986). Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. New England Journal of Medicine, 314(22), 1402-1406.

Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. / Salzman, E. W.; Weinstein, M. J.; Weintraub, R. M.; Ware, J. A.; Thurer, R. L.; Robertson, L.; Donovan, A.; Gaffney, T.; Bertele, V.; Troll, J.

In: New England Journal of Medicine, Vol. 314, No. 22, 1986, p. 1402-1406.

Research output: Contribution to journalArticle

Salzman, EW, Weinstein, MJ, Weintraub, RM, Ware, JA, Thurer, RL, Robertson, L, Donovan, A, Gaffney, T, Bertele, V & Troll, J 1986, 'Treatment with desmopressin acetate to reduce blood loss after cardiac surgery', New England Journal of Medicine, vol. 314, no. 22, pp. 1402-1406.
Salzman EW, Weinstein MJ, Weintraub RM, Ware JA, Thurer RL, Robertson L et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. New England Journal of Medicine. 1986;314(22):1402-1406.
Salzman, E. W. ; Weinstein, M. J. ; Weintraub, R. M. ; Ware, J. A. ; Thurer, R. L. ; Robertson, L. ; Donovan, A. ; Gaffney, T. ; Bertele, V. ; Troll, J. / Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. In: New England Journal of Medicine. 1986 ; Vol. 314, No. 22. pp. 1402-1406.
@article{1350e98c5beb4e189c6ca4ee6e54ac9e,
title = "Treatment with desmopressin acetate to reduce blood loss after cardiac surgery",
abstract = "Bleeding after cardiopulmonary bypass remains a cause for concern, requiring reexploration of the chest in approximately 3 percent of patients who have had operations on the heart. We examined the possibility that this problem might be alleviated by desmopressin acetate (DDAVP), which increases the plasma level of von Willebrand factor and improves hemostasis in mild hemophilia and other conditions associated with defective platelet function. In a double-blind, prospective, randomized trial, we studied the effect of intraoperative desmopressin acetate in 70 patients undergoing various cardiac operations requiring cardiopulmonary bypass. Patients undergoing uncomplicated primary coronary-artery bypass grafting were not included. The drug significantly reduced mean operative and early postoperative blood loss (1317 ± 486 ml in the treated group vs. 2210 ± 1415 ml in the placebo group); of the 14 patients whose 24-hour blood loss exceeded 2000 ml, 11 had received the placebo. Plasma levels of von Willebrand factor were higher after desmopressin acetate than after placebo. Patients with the most bleeding had relatively low levels of von Willebrand factor before operation, suggesting a role for this factor in the hemorrhagic tendency induced by extracorporeal circulation. There were no untoward side effects of desmopressin acetate. We conclude that the administration of desmopressin acetate can be recommended to reduce blood loss in patients undergoing complex cardiac operations. The beneficial effect of the drug on hemostasis after cardiopulmonary bypass may be related to its effect on von Willebrand factor.",
author = "Salzman, {E. W.} and Weinstein, {M. J.} and Weintraub, {R. M.} and Ware, {J. A.} and Thurer, {R. L.} and L. Robertson and A. Donovan and T. Gaffney and V. Bertele and J. Troll",
year = "1986",
language = "English",
volume = "314",
pages = "1402--1406",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "22",

}

TY - JOUR

T1 - Treatment with desmopressin acetate to reduce blood loss after cardiac surgery

AU - Salzman, E. W.

AU - Weinstein, M. J.

AU - Weintraub, R. M.

AU - Ware, J. A.

AU - Thurer, R. L.

AU - Robertson, L.

AU - Donovan, A.

AU - Gaffney, T.

AU - Bertele, V.

AU - Troll, J.

PY - 1986

Y1 - 1986

N2 - Bleeding after cardiopulmonary bypass remains a cause for concern, requiring reexploration of the chest in approximately 3 percent of patients who have had operations on the heart. We examined the possibility that this problem might be alleviated by desmopressin acetate (DDAVP), which increases the plasma level of von Willebrand factor and improves hemostasis in mild hemophilia and other conditions associated with defective platelet function. In a double-blind, prospective, randomized trial, we studied the effect of intraoperative desmopressin acetate in 70 patients undergoing various cardiac operations requiring cardiopulmonary bypass. Patients undergoing uncomplicated primary coronary-artery bypass grafting were not included. The drug significantly reduced mean operative and early postoperative blood loss (1317 ± 486 ml in the treated group vs. 2210 ± 1415 ml in the placebo group); of the 14 patients whose 24-hour blood loss exceeded 2000 ml, 11 had received the placebo. Plasma levels of von Willebrand factor were higher after desmopressin acetate than after placebo. Patients with the most bleeding had relatively low levels of von Willebrand factor before operation, suggesting a role for this factor in the hemorrhagic tendency induced by extracorporeal circulation. There were no untoward side effects of desmopressin acetate. We conclude that the administration of desmopressin acetate can be recommended to reduce blood loss in patients undergoing complex cardiac operations. The beneficial effect of the drug on hemostasis after cardiopulmonary bypass may be related to its effect on von Willebrand factor.

AB - Bleeding after cardiopulmonary bypass remains a cause for concern, requiring reexploration of the chest in approximately 3 percent of patients who have had operations on the heart. We examined the possibility that this problem might be alleviated by desmopressin acetate (DDAVP), which increases the plasma level of von Willebrand factor and improves hemostasis in mild hemophilia and other conditions associated with defective platelet function. In a double-blind, prospective, randomized trial, we studied the effect of intraoperative desmopressin acetate in 70 patients undergoing various cardiac operations requiring cardiopulmonary bypass. Patients undergoing uncomplicated primary coronary-artery bypass grafting were not included. The drug significantly reduced mean operative and early postoperative blood loss (1317 ± 486 ml in the treated group vs. 2210 ± 1415 ml in the placebo group); of the 14 patients whose 24-hour blood loss exceeded 2000 ml, 11 had received the placebo. Plasma levels of von Willebrand factor were higher after desmopressin acetate than after placebo. Patients with the most bleeding had relatively low levels of von Willebrand factor before operation, suggesting a role for this factor in the hemorrhagic tendency induced by extracorporeal circulation. There were no untoward side effects of desmopressin acetate. We conclude that the administration of desmopressin acetate can be recommended to reduce blood loss in patients undergoing complex cardiac operations. The beneficial effect of the drug on hemostasis after cardiopulmonary bypass may be related to its effect on von Willebrand factor.

UR - http://www.scopus.com/inward/record.url?scp=0022619402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022619402&partnerID=8YFLogxK

M3 - Article

VL - 314

SP - 1402

EP - 1406

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 22

ER -